There are two ways to think about this report from I-MAK that calculated that just four medicines -- Humira, Rituxan, Avastin and Lantus -- made more than $150 billion in
It’s a short newsletter today because my attention will be on Washington today. I plan to watch as much of the Senate hearing as I can stand. There’s a lot
I’ll have a bit tomorrow on the PBM lawsuit against the FTC, but if you’re looking for some PBM-related content today, you should check out Dr. Glaucomflecken on the legal